×
About 2,315,625 results

Fluconazole - fluconazole tablet-REMEDYREPACK INC.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d11e0926-cd15-49ba-b0ee-2b6d4e009dd8

Dec 30th, 2022 - Fluconazole tablets are indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, di...

Lingering Effects Seen With Non-COVID Respiratory Illness Too
https://www.medpagetoday.com/infectiousdisease/covid19/102011

Dec 1st, 2022 - People with acute respiratory illness during the pandemic suffered similar levels of poor well-being in the months afterward whether they tested positive for SARS-CoV-2 or not, a registry study showed. In a cohort of people who all had initial symptoms suggestive of COVID-19, those who had moderate to severe scores at 3 months on the pain, mood, and other quality-of-life measures on the Patient...

Long COVID Costs Trillions; 'Sunburnt Challenge' Banned; Diagnosis by Fart?
https://www.medpagetoday.com/infectiousdisease/covid19/101990

Dec 1st, 2022 - Note that some links may require subscriptions. One estimate has long COVID costing the U.S. economy $3.7 trillion. (CNBC) The FDA is considering a new strategy for blood donation that may include screening gay and bisexual men for individual risks. (CNN) Responding to criticism, ProPublica says it stands by its controversial investigation (published with Vanity Fair) that pins COVID-19's origi...

Year in Review: Diffuse Large B-Cell Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/101996

Dec 1st, 2022 - Second-line treatment for diffuse large B-cell lymphoma (DLBCL) got a big boost in 2022 with new indications for a pair of chimeric antigen receptor (CAR) T-cell therapies, while an antibody-drug conjugate moved one step closer to shaking up treatment in the first-line setting. CAR-T Products Move to Second-Line In April, axicabtagene ciloleucel (axi-cel; Yescarta) became the first CAR T-cell t...

Four Eyes Are Not Better Than Two for COVID-19 Protection
https://www.medpagetoday.com/infectiousdisease/covid19/101995

Dec 1st, 2022 - Wearing glasses in public for 2 weeks did not protect against SARS-CoV-2 infection, a Norwegian pragmatic randomized trial showed. Among more than 3,700 participants, 3.7% of those randomized to wear sunglasses or other types of glasses in the community reported a positive COVID test to the Norwegian Surveillance System for Communicable Diseases compared with 3.5% of those in the control group ...

Cortrosyn - cosyntropin injection, powder, lyophilized, for solution-Amphastar Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=746856e9-3930-4f6a-b8e6-a03845d6dd0b

Dec 1st, 2022 - CORTROSYN® (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION ...

Azithromycin - azithromycin dihydrate injection, powder, lyophilized, for solution-Slate Run Pharmaceuticals
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8acce3c1-f4be-4968-a71f-3ffd9fbaa4a4

Dec 1st, 2022 - Azithromycin for Injection is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Azithromycin for Injection is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria: Community-acquired pneumonia in adults...

Rowasa - mesalamine suspension-Meda Pharmaceuticals Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e505ab99-1943-4216-a178-4d5dbe64e3b2

Dec 1st, 2022 - ROWASA® (mesalamine) Rectal Suspension Enema is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults.

Can Cannabis Help Patients With MS?
https://www.medscape.com/viewarticle/977034

Dec 1st, 2022 - This transcript has been edited for clarity. Anne Cross, MD: Hello. I'm Anne Cross. Welcome to Medscape's InDiscussion series on multiple sclerosis. And today we're going to take on the somewhat controversial topic of the use of cannabis and cannabinoids in the treatment of symptoms in patients with multiple sclerosis. We have an expert to speak to us today about this, Dr Jacquelyn Bainbridge, ...

TikTok Creates Ozempic Shortage; New MS Framework Proposed; and AI May Cut Bias in Drug Trials
https://www.medscape.com/viewarticle/984741

Dec 1st, 2022 - TikTok Creates Ozempic Shortage TikTok is fueling demand for Ozempic, creating shortages of the diabetes drug now used for weight loss. Videos on TikTok hashtagged #ozempic have amassed more than 275 million views, and #ozempicweightloss has more than 110 million. The trend follows social media posts by celebrities such as Kim Kardashian and Elon Musk touting their own use of the drug or weight...

Association of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being 3 Months After a Symptomatic Illness
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799116
JAMA Network Open; Wisk LE, Gottlieb MA et. al.

Dec 1st, 2022 - Post–COVID-19 conditions (PCCs), often referred to as long COVID, are a heterogeneous group of conditions generally referring to symptoms that emerge, recur, or persist for more than 4 weeks after acute infection with SARS-CoV-2.1 Hallmarks of PCCs include fatigue, cognitive impairment, and postexertional malaise along with symptoms encompassing nearly every organ system.

Higher BMI a Risk Factor for Long COVID Symptoms
https://www.medpagetoday.com/primarycare/longcovid/101981

Nov 30th, 2022 - When it comes to developing long COVID, certain people may have a higher risk than others, researchers reported. According to an online survey of people who tested positive in 2020, 52.1% said they experienced post-COVID syndrome symptoms, said Vassilios Vassiliou, PhD, of the University of East Anglia in Norwich, England, and colleagues. One of the top predictors of exactly who might develop t...

Research - Association between Conflict and Cholera in Nigeria and the Democratic Republic of the Congo
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/732832

Research — Association between Conflict and Cholera in Nigeria and the Democratic Republic of the Congo

New Framework for Multiple Sclerosis Diagnosis, Treatment Proposed
https://www.medscape.com/viewarticle/984749

Nov 30th, 2022 - An international panel of experts has proposed a new way to classify multiple sclerosis (MS) that would ultimately change the way patients are diagnosed and treated. The goal is to eventually move away from the current system, which classifies MS based on disease progression into distinct relapsing-remitting, secondary progressive, and primary progressive subtypes. Members of the International ...

New Genetic Variant Linked to Maturity-Onset Diabetes of the Young
https://www.medscape.com/viewarticle/984757

Nov 30th, 2022 - A newly discovered genetic variant that is associated with type 2 diabetes (T2D) is responsible for almost 7% of all diabetes cases in Greenland, according to a whole-genome sequencing analysis of 448 Greenlandic Inuit individuals. The variant, identified as c.1108G>T, "has the largest population impact of any previously reported variant" within the HNF1A gene – a gene that can cause maturity-o...

Tick-Borne Pathogens Becoming More Widespread in Central Canada
https://www.medscape.com/viewarticle/984763

Nov 30th, 2022 - Tick-borne pathogens, which cause illnesses such as Lyme disease and Rocky Mountain spotted fever, are becoming more widespread in Canada and are posing risks in new areas, according to a new study. Five emerging pathogens were detected across Ontario and Quebec, including some that had moved outside of their historic geographic range. Kirsten Crandall "In Canada, emerging tick-borne pathogens ...

Rituximab Raises Remission Rate in GPA Vasculitis
https://www.medscape.com/viewarticle/984760

Nov 30th, 2022 - More patients with granulomatosis with polyangiitis (GPA) were in remission at 6 months if they had received rituximab (Rituxan) rather than cyclophosphamide (Cytoxan) as induction therapy, according to a target trial emulation performed by the French Vasculitis Study Group (FVSG). Remission, which was defined as a score of zero on the validated Birmingham Vasculitis Activity Score (BVAS) and u...

Elderly Now Account for Almost 90% of COVID-19 Deaths, Data Show
https://www.medscape.com/viewarticle/984771

Nov 30th, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Almost 9 out of 10 COVID-19 deaths are among people 65 and older -- the highest rate yet for elderly fatalities since the pandemic began, according to an analysis by The Washington Post. The Centers for Disease Control says more than 300 people die each day from COVID-19 – down from the 2,000 or...

No Help From Vitamin D Supplements; COVID-19 Severity Linked to Genes; and Salting Food Less Lowers Cardiac Risk
https://www.medscape.com/viewarticle/984694

Nov 30th, 2022 - No Help From Vitamin D Supplements A new study adds to evidence that vitamin D supplements don't do much for health, said Medscape writer F. Perry Wilson, MD, MSCE, of the Yale School of Medicine. Children in Ulaanbaatar, Mongolia, showed no difference in the rate of latent tuberculosis infection after 3 years of vitamin D3 supplements compared with children who got only a placebo, according to...

Researchers Take Aim at One Vaccine Targeting COVID, Flu, Even RSV
https://www.medscape.com/viewarticle/984795

Nov 30th, 2022 - With multiple viruses circulating around the United States and multiple vaccines to try to prevent some of them, there is increasing effort to streamline and improve the process and ultimately make one vaccine to attack most — if not all — of the viruses at the same time. Scientists are trying several approaches to stay ahead of not only influenza and SARS-Cov-2, but also respiratory syncytial ...